Shares of Nuvation Bio dropped 6.2% to $5.98 after the oncology company's second-quarter results delivered an uncomfortable split decision: strong drug sales but a wider-than-expected loss. The company achieved $31.7 million in total Q2 revenue, including $23.2 million in net product revenue for its lung cancer drug IBTROZI. That topped the roughly $26.5 million consensus estimate. But earnings per share came in at a loss of $0.18, worse than the -$0.15 Wall Street had penciled in. For a stock that had climbed from under $4 a year ago, the miss raised a pointed question: can this company turn accelerating sales into actual profits?
Drug Sales Are Growing Fast, but the Cash Register Still Shows Red
IBTROZI delivered $23.2 million in net product revenue, a 25% jump from Q1's $18.5 million, reflecting continued adoption.
The drug is now the most prescribed therapy of its kind for a specific type of advanced lung cancer in both first-line and overall new patient starts in 2026, based on claims data from the first five months of the year. Yet the three-cent EPS miss signals that spending on the drug's launch, pipeline research, and corporate overhead is growing at least as fast as revenue — a pattern that spooks investors who expected profitability to come into view sooner.
New Patients Keep Coming, Especially the Most Valuable Ones
About 85% of the roughly 160 new patients who started IBTROZI in Q2 were treatment-naïve — meaning they hadn't tried another similar drug first — representing roughly 30% quarter-over-quarter growth in that group. First-line patients tend to stay on therapy longer, generating more durable revenue streams. That mix shift is arguably the most encouraging signal in the report.
A $661 Million War Chest Buys Time — but Also Masks the Burn
Nuvation ended June with $661 million in cash and investments, not counting an additional $36.5 million secured in July from a convertible debt offering. That's ample runway, but it also reflects recent borrowing. The operating margin sits at roughly -81% , a reminder that this is still a company spending far more than it earns.
Regulatory Milestones Could Shift the Math
The UK's drug regulator has accepted a marketing application from partner Eisai, and the FDA accepted a supplemental application with updated clinical data, targeting a January decision. International approvals and label expansions would widen the addressable patient pool — the only realistic path to offsetting the heavy spending investors just punished.